期刊文献+

普乐可复治疗儿童难治性肾病综合征的疗效及其对患儿血清相关炎性因子的影响研究

Efficacy of Tacrolimus capsules in the treatment of children with refractory nephrotic syndrome and its effect on related serum inflammatory factors
下载PDF
导出
摘要 目的 研究普乐可复治疗难治性肾病综合征的疗效及其对患儿血清相关炎性因子的影响.方法 将我院收治的难治性肾病综合征75例随机分为两组,两组均给予激素治疗,实验组38例在激素治疗基础上给予普乐可复治疗,对照组37例在激素治疗基础上给予环磷酰胺治疗,对比两组的临床疗效及对患儿血清相关炎性因子的影响.结果 实验组、对照组总有效率分别为94.71%、72.97%,实验组治疗后血清IL-2[(190.15±14.18) pg·ml-1]、sIL-2R[(183.14±17.84)U/ml]、甘油三脂[(1.98±0.64)U/L]、血浆白蛋白[(44.87±6.85) g/L]、24h尿蛋白[(0.75±0.14)mg]改善较对照组治疗后明显,两组比较差异有统计学意义(P<0.05).结论 普乐可复治疗难治性肾病综合征,疗效显著,血清IL-2、sIL-2R、甘油三脂、血浆白蛋白、24 h尿蛋白改善明显,效果较为理想. Objective To study the efficacy of Tacrolimus capsules in the treatment of children with refractory nephrotic syndrome and its effect on related serum inflammatory factors.Methods 75 cases of refractory nephrotic syndrome in our hospital were randomly divided into two groups.Two groups were treated with hormone therapy, 38 cases in experimental group received Tacrolimus capsules, 37 cases in control group received cyclophosphamide.Compared the clinical efficacy of two groups and related serum inflammatory factors.Results The total effective rate in experimental group and control group were 94.71%, 72.97% respectively.After treatment, serum IL-2 [(190.15±14.18)pg/ml], sIL-2R [(183.14±17.84) U/ml], triglycerides [(1.98±0.64)U/L], serum albumin [(44.87±6.85)g/L], 24 h urine protein [(0.75±0.14) mg] in experimental group improved more significantly that those in control group (P〈0.05).Conclusion Tacrolimus capsules in the treatment of children with refractory nephrotic syndrome has a significant effect, with serum IL-2, sIL-2R, triglycerides, serum albumin, 24 h urine protein improving significantly.
作者 牛银萍
出处 《国际医药卫生导报》 2015年第20期3051-3054,共4页 International Medicine and Health Guidance News
关键词 难治性肾病综合征 普乐可复 疗效 血清相关炎性因子 Refractory nephrotic syndrome Tacrolimus capsules Efficacy Related serum inflammatory factors
  • 相关文献

参考文献6

二级参考文献39

  • 1项新,黄典胜,施燕春,梁延秀,黄振华,何坤,陆玲娜.转化生长因子β1基因-509C/T多态性与原发性肾病综合征相关关系的研究[J].中国全科医学,2013,16(8):884-887. 被引量:3
  • 2张德瑄.小儿肾病综合征发病机制的研究进展(综述)[J].临床儿科杂志,1995,13(5):350-351. 被引量:3
  • 3Smith K A. Interleukin 2, inception, impact, and implications [ J]. Science, 1988;240(4856): 1169.
  • 4Rubin L A, Nelson D L. The soluble interleukin 2 receptor, biology function and clinical application [J]. Ann Inter Med, 1990; 113(8):619.
  • 5Chrul S, Zochniak K, Zochniak J et al. CD3-CD25 lymphocyte population and blood serum IL-2R in children with liponephrosis [ J ]. Pol Merkuriusz Lek, 2000; 8(46): 214.
  • 6Goto T, Kino T, Halanaka H et al. Discovery of FK506, a noval immunosupprasant isolated from streptomyces tsukubaensis [ J ]. Transplant Proc, 1987;19(1) :4.
  • 7Shaw K T, Ho A M, Raghavan A et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFATI in stimulated immune cells [J] .Proc Nall Acad Sci USA, 1995;92(24) :11205.
  • 8Inamura N, Nakahara K, Kino T et al. Prolongation of skin allograft survival in rats by a novel immunesuppressive agent, FK506 [J]. Transplantation, 1988;45(1):206.
  • 9May A D. Tacrolimus as baseline immunosuppression in kidney transplantation [J]. New Horizons in Kidney Transplantation, 1999; ( 1 ): 10.
  • 10Alejandro R. Jadad,R.Andrew Moore,Dawn Carroll,Crispin Jenkinson,D.John M. Reynolds,David J. Gavaghan,Henry J. McQuay.Assessing the quality of reports of randomized clinical trials: Is blinding necessary?[J].Controlled Clinical Trials.1996(1)

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部